RU2012136624A - Фармацевтические композиции для лечения боли и других показаний - Google Patents
Фармацевтические композиции для лечения боли и других показаний Download PDFInfo
- Publication number
- RU2012136624A RU2012136624A RU2012136624/15A RU2012136624A RU2012136624A RU 2012136624 A RU2012136624 A RU 2012136624A RU 2012136624/15 A RU2012136624/15 A RU 2012136624/15A RU 2012136624 A RU2012136624 A RU 2012136624A RU 2012136624 A RU2012136624 A RU 2012136624A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- halogen
- mono
- optionally substituted
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 26
- 208000002193 Pain Diseases 0.000 title claims 23
- 125000000217 alkyl group Chemical group 0.000 claims abstract 188
- 229910052736 halogen Inorganic materials 0.000 claims abstract 127
- 150000002367 halogens Chemical class 0.000 claims abstract 95
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 72
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 41
- 125000001424 substituent group Chemical group 0.000 claims abstract 37
- 125000003118 aryl group Chemical group 0.000 claims abstract 26
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims abstract 3
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims abstract 3
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims abstract 3
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims abstract 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- -1 (2) pyridinyl Chemical group 0.000 claims 74
- 125000005843 halogen group Chemical group 0.000 claims 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 25
- 239000003940 fatty acid amidase inhibitor Substances 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 208000004296 neuralgia Diseases 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 208000005171 Dysmenorrhea Diseases 0.000 claims 6
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 208000004454 Hyperalgesia Diseases 0.000 claims 6
- 208000019695 Migraine disease Diseases 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 206010027599 migraine Diseases 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 238000001356 surgical procedure Methods 0.000 claims 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 208000030814 Eating disease Diseases 0.000 claims 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 5
- 230000036506 anxiety Effects 0.000 claims 5
- 235000014632 disordered eating Nutrition 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 4
- 206010047700 Vomiting Diseases 0.000 claims 4
- 208000005298 acute pain Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 230000003492 excitotoxic effect Effects 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 208000019116 sleep disease Diseases 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 229910052722 tritium Inorganic materials 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000035154 Hyperesthesia Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000004550 Postoperative Pain Diseases 0.000 claims 3
- 206010053552 allodynia Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 3
- 238000002224 dissection Methods 0.000 claims 3
- 231100000869 headache Toxicity 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 208000004371 toothache Diseases 0.000 claims 3
- 208000009935 visceral pain Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010003497 Asphyxia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 238000012084 abdominal surgery Methods 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 231100000318 excitotoxic Toxicity 0.000 claims 2
- 231100000063 excitotoxicity Toxicity 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 235000020932 food allergy Nutrition 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000003243 intestinal obstruction Diseases 0.000 claims 2
- 230000004410 intraocular pressure Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 208000012866 low blood pressure Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 239000002581 neurotoxin Substances 0.000 claims 2
- 231100000618 neurotoxin Toxicity 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 230000001769 paralizing effect Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 201000009881 secretory diarrhea Diseases 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical group C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 1
- 229960004945 etoricoxib Drugs 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000004385 trihaloalkyl group Chemical group 0.000 abstract 2
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical group Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29908710P | 2010-01-28 | 2010-01-28 | |
| US61/299,087 | 2010-01-28 | ||
| PCT/US2011/022412 WO2011094209A1 (en) | 2010-01-28 | 2011-01-25 | Pharmaceutical compositions for the treatment of pain and other indicatons |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012136624A true RU2012136624A (ru) | 2014-03-10 |
Family
ID=44319717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012136624/15A RU2012136624A (ru) | 2010-01-28 | 2011-01-25 | Фармацевтические композиции для лечения боли и других показаний |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130030000A1 (OSRAM) |
| EP (1) | EP2528603A4 (OSRAM) |
| JP (1) | JP2013518110A (OSRAM) |
| KR (1) | KR20120123691A (OSRAM) |
| CN (1) | CN102858338A (OSRAM) |
| AU (1) | AU2011209754A1 (OSRAM) |
| BR (1) | BR112012018913A2 (OSRAM) |
| CA (1) | CA2786888A1 (OSRAM) |
| MX (1) | MX2012008801A (OSRAM) |
| RU (1) | RU2012136624A (OSRAM) |
| WO (1) | WO2011094209A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2732526A1 (en) * | 2008-08-04 | 2010-02-11 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of faah |
| AU2011238487B2 (en) * | 2010-04-08 | 2015-10-01 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as modulators of FAAH |
| WO2011133444A1 (en) | 2010-04-21 | 2011-10-27 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| EP2582373A4 (en) | 2010-06-16 | 2013-10-30 | Bruce Chandler May | USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COLLECTIONS AND INFLAMMATION |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| WO2014164285A2 (en) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| ES2660494T3 (es) | 2013-03-13 | 2018-03-22 | 14779507 | Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática |
| CA2901421A1 (en) | 2013-03-13 | 2014-10-09 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
| JP6483666B2 (ja) | 2013-10-14 | 2019-03-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
| WO2015057659A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| PL3077047T3 (pl) * | 2013-12-04 | 2019-10-31 | Galmed Res & Development Ltd | Sole aramcholu |
| WO2016036588A1 (en) * | 2014-09-03 | 2016-03-10 | Merck Sharp & Dohme Corp. | Pharmaceutical suspensions containing etoricoxib |
| EP3193875B1 (en) | 2014-09-15 | 2022-02-16 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| PL3595665T3 (pl) * | 2017-03-13 | 2025-01-13 | Lundbeck La Jolla Research Center, Inc. | Podwójne inhibitory magl i faah |
| WO2019008115A1 (en) | 2017-07-07 | 2019-01-10 | Syngenta Participations Ag | HETEROCYCLIC DERIVATIVES HAVING PESTICIDE ACTIVITY HAVING SUBSTITUENTS CONTAINING SULFUR |
| KR102257685B1 (ko) | 2018-09-20 | 2021-05-31 | 성균관대학교산학협력단 | Cox-2 억제제를 유효성분으로 포함하는 소염진통 예방 또는 치료용 정제 조성물 |
| CN110156710B (zh) * | 2019-04-30 | 2022-10-28 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种多取代噁唑类化合物的制备方法 |
| JP7464955B2 (ja) | 2020-02-27 | 2024-04-10 | 国立大学法人千葉大学 | ヨードオキサゾール化合物の製造方法、オキサゾール化合物の製造方法 |
| WO2021236518A1 (en) * | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| WO2022251707A1 (en) * | 2021-05-28 | 2022-12-01 | Ananda Scientific, Inc. | Methods for the treatment of post-traumatic stress disorder and traumatic brain injury with cannabinoids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA008767B1 (ru) * | 2002-10-08 | 2007-08-31 | Зе Скрипс Ресеч Инститьют | Ингибиторы гидролазы амидов жирных кислот |
| HRP20150765T1 (hr) * | 2004-12-30 | 2015-10-09 | Janssen Pharmaceutica N.V. | Amid derivati piperidin- i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za lijeäśenje tjeskobe, boli i drugih stanja |
| EP1866293A1 (en) * | 2005-03-31 | 2007-12-19 | UCB Pharma, S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| AU2008257154B2 (en) * | 2007-05-25 | 2014-03-06 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| JP2011523959A (ja) * | 2008-06-11 | 2011-08-25 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｆａａｈの阻害剤として有用なイミダゾール誘導体 |
| JP2011524872A (ja) * | 2008-06-11 | 2011-09-08 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｆａａｈの阻害剤として有用なピラゾール誘導体 |
| CA2732526A1 (en) * | 2008-08-04 | 2010-02-11 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of faah |
-
2011
- 2011-01-25 CN CN2011800171616A patent/CN102858338A/zh active Pending
- 2011-01-25 EP EP11737514.7A patent/EP2528603A4/en not_active Withdrawn
- 2011-01-25 US US13/574,303 patent/US20130030000A1/en not_active Abandoned
- 2011-01-25 RU RU2012136624/15A patent/RU2012136624A/ru not_active Application Discontinuation
- 2011-01-25 WO PCT/US2011/022412 patent/WO2011094209A1/en not_active Ceased
- 2011-01-25 KR KR1020127022379A patent/KR20120123691A/ko not_active Withdrawn
- 2011-01-25 JP JP2012551232A patent/JP2013518110A/ja not_active Withdrawn
- 2011-01-25 MX MX2012008801A patent/MX2012008801A/es not_active Application Discontinuation
- 2011-01-25 AU AU2011209754A patent/AU2011209754A1/en not_active Abandoned
- 2011-01-25 CA CA2786888A patent/CA2786888A1/en not_active Abandoned
- 2011-01-25 BR BR112012018913A patent/BR112012018913A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102858338A (zh) | 2013-01-02 |
| MX2012008801A (es) | 2012-08-17 |
| EP2528603A4 (en) | 2013-09-04 |
| EP2528603A1 (en) | 2012-12-05 |
| BR112012018913A2 (pt) | 2017-06-20 |
| US20130030000A1 (en) | 2013-01-31 |
| AU2011209754A1 (en) | 2012-07-26 |
| CA2786888A1 (en) | 2011-08-04 |
| WO2011094209A1 (en) | 2011-08-04 |
| JP2013518110A (ja) | 2013-05-20 |
| KR20120123691A (ko) | 2012-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012136624A (ru) | Фармацевтические композиции для лечения боли и других показаний | |
| JP2013518110A5 (OSRAM) | ||
| ES2651132T3 (es) | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante | |
| CA2650954C (en) | Bicyclic derivatives as cetp inhibitors | |
| CN110573501A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| JP7142022B2 (ja) | Ｍａｌｔ１の阻害剤およびそれらの使用 | |
| RU2014114466A (ru) | ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА | |
| HRP20170447T1 (hr) | Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini | |
| JP2016053042A5 (OSRAM) | ||
| HRP20070327T3 (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| JP6502332B2 (ja) | 二環式アルキン誘導体およびその使用 | |
| UA119835C2 (uk) | ПОХІДНІ ПІРАЗОЛО[1,5-а]ПІРАЗИН-4-ІЛУ ЯК JAK-ІНГІБІТОРИ | |
| JP2012533541A5 (OSRAM) | ||
| EP3092235A2 (en) | Novel inhibitors of glutaminase | |
| HRP20211542T1 (hr) | Tetrasupstituirani spojevi alkena i njihova uporaba | |
| CA2798222A1 (en) | Pyrazolopyridines as inhibitors of the kinase lrrk2 | |
| JP2016525075A5 (OSRAM) | ||
| RU2013114852A (ru) | Оксопиперазин-азетин амиды и оксодиазепин-азетидин амиды в качестве ингибиторов моноацилглицерол липазы | |
| JP2020519584A (ja) | アポトーシスシグナル調節キナーゼ１阻害剤およびその使用方法 | |
| JP2017508795A5 (OSRAM) | ||
| JP2013540712A5 (OSRAM) | ||
| JP2020529419A5 (OSRAM) | ||
| PE20161369A1 (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona | |
| RU2016137356A (ru) | Соединение нафтиламида, способ его получения и применение | |
| EP4622970A1 (en) | Inhibitors of ripk2 and medical uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150513 |